Fisher & Paykel Healthcare (ASX:FPH) share price on watch after reporting huge profit growth

The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price will be on watch on Thursday following the release of a strong full year result…

| More on:
Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price will be one to watch on Thursday.

This follows the release of the medical device company's full year results this morning.

How did Fisher & Paykel Healthcare perform in FY 2021?

Fisher & Paykel Healthcare was a very positive performer in FY 2021, delivering a record full year result.

According to the release, for the 12 months ended 31 March, the company reported a 56% increase in operating revenue to NZ$1.97 billion. And thanks to margin expansion, the company's net profit after tax jumped 82% to NZ$524 million.

This compares very favourably to the guidance given with its half year results of revenue of ~NZ$1.72 billion and net profit after tax of NZ$400 million to NZ$415 million.

What were the drivers of its growth?

The key driver of its growth was its Hospital Product segment, which recorded an 87% increase in revenue to NZ$1.5 billion. This represents 76% of the company's operating revenue.

Fisher & Paykel Healthcare's Managing Director and CEO, Lewis Gradon, commented: "The unprecedented result was driven by our Hospital product group, which includes Optiflow and Airvo systems used to deliver nasal high flow therapy. Sales of our Hospital hardware and consumables have continued to track COVID-19 hospitalisation surges in countries around the world,"

"Although COVID-19 restrictions impacted sleep clinics and reduced OSA diagnosis rates, revenue for the Homecare product group was $466 million, an increase of 2% over the previous year, or 4% in constant currency," added Gradon.

Outlook

Due to ongoing COVID-19 uncertainties, Fisher & Paykel Healthcare is unable to provide guidance for FY 2022.

Mr Gradon explained: "We expect our Hospital and Homecare revenue for FY22 to be impacted by the number of COVID-19 related hospitalisations around the world. There is a wide range of scenarios for both the timing of a 'return to normal' and to what extent a return to normal includes COVID-19 endemic hospitalisations. It is unclear at this stage when and if other respiratory hospitalisations and surgical procedures will return to pre-COVID levels, or whether countries will increase their investment in healthcare infrastructure."

Though, the company has provided an update on current trading.

It advised: "In the financial year so far, Hospital revenue continues to remain variable with higher volumes of Hospital hardware and consumables to locations with hospitalisation surges and an ongoing shift towards Optiflow nasal high flow therapy. OSA shows signs of recovery after a slower fourth quarter."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

10 Aussie stocks to buy in FY 2026

Let's see which shares analysts think could be buys in the upcoming financial year.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to the trading week for investors this Friday.

Read more »

A young boy points and smiles as he eats fried chicken.
Share Gainers

3 ASX All Ords shares smashing the benchmark this week

Investors are sending these three ASX All Ords shares rocketing 18% to more than 29% this week. But why?

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why APA, Flight Centre, Reece, and Transurban shares are falling today

These shares are having a tough finish to the week. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Alliance Aviation, BHP, Boss Energy, and Orthocell shares are racing higher

These shares are ending the week on a positive note. But why?

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »